Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.47 |
| ▸ | CTSB | P07858 | 5/20 | 0.47 |
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | CTSK | P43235 | 5/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 6/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19915074 | 0.85 | NPC1 (0.44) | CTSLCTSBCTSSCTSKGRM4 | |
| SCHEMBL1704674 | 0.82 | KDM1A (0.53) | CTSLCTSBCTSSCTSKKDM1A | |
| SCHEMBL27478239 | 0.82 | CTSL (0.42) | CTSLCTSBCTSSCTSKHTR6 | |
| SCHEMBL9984392 | 0.79 | HDAC8 (0.48) | CTSLCTSBCTSSCTSKHTR6 | |
| SCHEMBL381677 | 0.79 | TRPA1 (0.53) | CTSLCTSBCTSSCTSKCHEK1 | |
| Hydrochloric Acid SCHEMBL382423 | 0.78 | HDAC8 (0.47) | CTSLCTSBCTSSCTSKHTR6 | |
| Hydrochloric Acid SCHEMBL381432 | 0.78 | TRPA1 (0.52) | CTSLCTSBCTSSCTSKHTR6 | |
| SCHEMBL12184793 | 0.77 | KDM1A (0.44) | CTSLCTSBCTSSCTSKKDM1A | |
| SCHEMBL4399289 | 0.77 | CTSL (0.44) | CTSLCTSBCTSSCTSKKDM1A | |
| SCHEMBL26125585 | 0.76 | TRPV4 (0.46) | MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130317041-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-11-28 | — | — | US | disclosed |
| US-8536182-B2 | Benzylpiperazine derivatives and their medical use | GLAXO GROUP LIMITED (GB) | 2013-09-17 | — | — | US | disclosed |
| CN-101258143-B | Benzylpiperazine derivatives and their medical use | GLAXO GROUP LTD | 2012-12-26 | — | — | CN | disclosed |
| EP-1907374-B1 | Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LTD (GB) | 2012-08-22 | — | — | EP | disclosed |
| EP-2441763-A1 | Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders | Glaxo Group Limited (GB) | 2012-04-18 | — | — | EP | disclosed |
| US-20090054456-A1 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | US | disclosed |
| CN-101258143-A | Benzylpiperazine derivatives and their medical use | GLAXO GROUP LTD (GB) | 2008-09-03 | — | — | CN | disclosed |
| EP-1907374-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007012479-A2 | BENZYLPIPERAZINE DERIVATES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054456-A1 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE | GPR68, GPR88, GPR55 | CTSL 3474/4885CTSB 3332/4885CTSS 3765/4885 |
| US-20130317041-A1 | COMPOUNDS | GPR68, GPR88, GPR35 | CTSL 2852/4885CTSB 2762/4885CTSS 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.